RECORD // Company

Odyssey Therapeutics, Inc.

Built 2026-11-22T03:04:08Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)
Matched by name only, not merged (5)

These records carry the same exact name as this company, but a name alone is not proof, so Seraphix holds them apart until name matching is verified (score due 11-21).

  • Odyssey Therapeutics, Inc. · Ca business · same registered legal name as 'Odyssey Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • Odyssey Therapeutics, Inc. · Ctgov · same registered legal name as 'Odyssey Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • ODYSSEY THERAPEUTICS · Epa echo · exact name match to 'Odyssey Therapeutics, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare
  • ODYSSEY THERAPEUTICS INC · Epa echo · same registered legal name as 'Odyssey Therapeutics, Inc.' Possible match based on name, not a shared identifier. Compare the records. Compare
  • ODYSSEY THERAPEUTICS · Epa rcra · exact name match to 'Odyssey Therapeutics, Inc.' (no other entity shares the name) Possible match based on name, not a shared identifier. Compare the records. Compare

5 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-04 · accession 0001193125-26-446208

ItemValuePeriodFormFiledAccessionReport
Revenue$03 months ended 2026-09-3010-Q2026-11-040001193125-26-4462082026-11-22 03:04 UTCReport an error
Net income (loss)$-53,059,0003 months ended 2026-09-3010-Q2026-11-040001193125-26-4462082026-11-22 03:04 UTCReport an error
Interest expense$12,0003 months ended 2026-09-3010-Q2026-11-040001193125-26-4462082026-11-22 03:04 UTCReport an error
Cash and cash equivalents$80,641,000at 2026-09-3010-Q2026-11-040001193125-26-4462082026-11-22 03:04 UTCReport an error
Contract liabilities (total)$0at 2026-09-3010-Q2026-11-040001193125-26-4462082026-11-22 03:04 UTCReport an error

Negative as reported in the filing.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001882782
Ticker
ODTX
EIN
863384382
CUSIP
67613T104
Record ID
sx:sec:0001882782

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

27 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-05SEC EDGAR company profile2026-11-22 03:04 UTCReport an error
SIC industry2836 Biological Products, (No Diagnostic Substances)2026-11-05SEC EDGAR company profile2026-11-22 03:04 UTCReport an error
State of incorporationDE2026-11-05SEC EDGAR company profile2026-11-22 03:04 UTCReport an error
Fiscal year end (MMDD)12312026-11-05SEC EDGAR company profile2026-11-22 03:04 UTCReport an error
Business address51 SLEEPER STREET, BOSTON, MA, 022102026-11-05SEC EDGAR company profile2026-11-22 03:04 UTCReport an error
ExchangesNasdaq2026-11-05SEC EDGAR company profile2026-11-22 03:04 UTCReport an error
Form D total offering amount (D filed 2025-12-04)$214,025,2002025-12-04D2026-11-22 03:04 UTCReport an error
Form D total amount sold (D filed 2025-12-04)$214,025,2002025-12-04D2026-11-22 03:04 UTCReport an error
Form D industry groupBiotechnology2025-12-04D2026-11-22 03:04 UTCReport an error
Form D revenue rangeDecline to Disclose2025-12-04D2026-11-22 03:04 UTCReport an error
Form D date of first sale2025-06-162025-12-04D2026-11-22 03:04 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-04)On November 4, 2026, Odyssey Therapeutics, Inc. (the "Company") announced its financial results for the three months ended September 30, 2026. A copy of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed "filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as…2026-11-04SEC EDGAR 8-K 0001193125-26-446174 (text as filed, excerpt)2026-11-22 03:04 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-10-20)On October 20, 2026, Odyssey Therapeutics, Inc. (the “Company”) issued a press release titled "Odyssey Therapeutics Presents Completed Phase 2a OD-001 Induction Results Strengthening Clinical Proof of Concept at UEG Week 2026" and posted a corporate presentation on its website at https://investors.odysseytx.com/news-events/presentations. A copy of each of the press release and presentation is furnished herewith as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K. The information contained in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 and Exhibit 99.2 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of…2026-10-20SEC EDGAR 8-K 0001193125-26-425684 (text as filed, excerpt)2026-11-22 03:04 UTCReport an error
8-K Item 7.01, Regulation FD Disclosure (filed 2026-09-09)On September 8, 2026, Odyssey Therapeutics, Inc. (the “Company”) posted a corporate presentation on its website at https://investors.odysseytx.com/news-events/presentations. A copy of the presentation is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific…2026-09-09SEC EDGAR 8-K 0001193125-26-385477 (text as filed, excerpt)2026-11-22 03:04 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-08-04)On August 4, 2026, Odyssey Therapeutics, Inc. (the "Company") announced its financial results for the three months ended June 30, 2026. A copy of the press release issued in connection with the announcement is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is intended to be furnished and shall not be deemed "filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or…2026-08-04SEC EDGAR 8-K 0001193125-26-331512 (text as filed, excerpt)2026-11-22 03:04 UTCReport an error
Plan (pension, plan no. 001)ODYSSEY THERAPEUTICS 401K RETIREMENT PLAN: 124 participants2025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-22 03:04 UTCReport an error
Plan (welfare, plan no. 501)ODYSSEY THERAPEUTICS GROUP HEALTH AND WELFARE PLAN: 87 participants2025-12-31DOL EBSA Form 5500 public datasets (dataset)2026-11-22 03:04 UTCReport an error
Largest institutional holder #1 (13F as filed): FMR LLC$96,903,9922026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:04 UTCReport an error
Largest institutional holder #2 (13F as filed): SR One Capital Management, LP$71,002,2612026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:04 UTCReport an error
Largest institutional holder #3 (13F as filed): TPG GP A, LLC$69,042,6322026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:04 UTCReport an error
Largest institutional holder #4 (13F as filed): LIGHTSPEED MANAGEMENT COMPANY, L.L.C.$67,513,9692026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:04 UTCReport an error
Largest institutional holder #5 (13F as filed): ORBIMED ADVISORS LLC$56,152,4152026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:04 UTCReport an error
Largest institutional holder #6 (13F as filed): Sanofi$37,268,7862026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:04 UTCReport an error
Largest institutional holder #7 (13F as filed): DEERFIELD MANAGEMENT COMPANY, L.P.$19,573,2612026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:04 UTCReport an error
Largest institutional holder #8 (13F as filed): Sands Capital Alternatives, LLC$16,371,2502026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:04 UTCReport an error
Largest institutional holder #9 (13F as filed): HHLR ADVISORS, LTD.$15,560,2842026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:04 UTCReport an error
Largest institutional holder #10 (13F as filed): General Catalyst Group Management, LLC$15,160,1892026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 03:04 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.